Zobrazeno 1 - 10
of 283
pro vyhledávání: '"Dale E, Bredesen"'
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1776 (2024)
Arguably, the most important parameter in treating cognitive decline associated with Alzheimer’s disease is the length of time in which improvement, if achieved at all, is sustained. However, monotherapies such as donepezil and memantine are associ
Externí odkaz:
https://doaj.org/article/e216612063e44cd08cafc31c399c54b0
Autor:
Rammohan V Rao, Sharanya Kumar, Julie Gregory, Christine Coward, Sho Okada, William Lipa, Lance Kelly, Dale E Bredesen
Publikováno v:
Biomedicines, Vol 9, Iss 10, p 1348 (2021)
Background: Alzheimer’s disease (AD) is the major cause of age-associated cognitive decline, and in the absence of effective therapeutics is progressive and ultimately fatal, creating a dire need for successful prevention and treatment strategies.
Externí odkaz:
https://doaj.org/article/196c4101efc14a238d73a664560dad78
Publikováno v:
Biomolecules, Vol 11, Iss 4, p 543 (2021)
Background—Alzheimer’s disease (AD) is a multifactorial, progressive, neurodegenerative disease that is characterized by memory loss, personality changes, and a decline in cognitive function. While the exact cause of AD is still unclear, recent s
Externí odkaz:
https://doaj.org/article/51cbaedab18b4992b30faf02a29aa026
Autor:
Kat Toups, Ann Hathaway, Deborah Gordon, Henrianna Chung, Cyrus Raji, Alan Boyd, Benjamin D. Hill, Sharon Hausman-Cohen, Mouna Attarha, Won Jong Chwa, Michael Jarrett, Dale E. Bredesen
Publikováno v:
Journal of Alzheimer's disease : JAD. 88(4)
Background: Effective therapeutics for Alzheimer’s disease are needed. However, previous clinical trials have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, which may be unrelated to the primary drive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df236e16453e6b1f488e7e442056a12b
https://pubmed.ncbi.nlm.nih.gov/35811518
https://pubmed.ncbi.nlm.nih.gov/35811518
Autor:
Mary Kay, Ross, Cyrus, Raji, Kristine L, Lokken, Dale E, Bredesen, Jared C, Roach, Cory C, Funk, Nathan, Price, Noa, Rappaport, Leroy, Hood, James R, Heath
Publikováno v:
J Alzheimers Dis Parkinsonism
We report a case of a patient with mixed dementia successfully treated with a personalized multimodal therapy. Monotherapeutics are inadequate for the treatment of Alzheimer’s disease (AD) and mixed dementia; therefore, we approach treatment throug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a23115c0b4bbc0ebe912c217ea9c5fa
https://pubmed.ncbi.nlm.nih.gov/35237464
https://pubmed.ncbi.nlm.nih.gov/35237464
Autor:
Dale E. Bredesen, Varghese John
Publikováno v:
EMBO Molecular Medicine, Vol 5, Iss 6, Pp 795-798 (2013)
Abstract To date, no truly effective therapy has been developed for Alzheimer's disease or mild cognitive impairment. In searching for new approaches that may succeed where previous ones have failed, it may be instructive to consider the successful t
Externí odkaz:
https://doaj.org/article/06431f593b844f8e9211b51dc3f28b94
Autor:
Rammohan V. Rao, Kaavya G. Subramaniam, Julie Gregory, Aida L. Bredesen, Christine Coward, Sho Okada, Lance Kelly, Dale E. Bredesen
Publikováno v:
International Journal of Molecular Sciences. 24:1659
Alzheimer’s disease (AD) is a multifactorial, progressive, neurodegenerative disease typically characterized by memory loss, personality changes, and a decline in overall cognitive function. Usually manifesting in individuals over the age of 60, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6037b7b7b97c4f2384681d637737c026
https://doi.org/10.3390/ijms24021659
https://doi.org/10.3390/ijms24021659
Autor:
Christine Coward, Sharanya Kumar, Dale E. Bredesen, Julie Gregory, Sho Okada, Lance Kelly, Rammohan V. Rao, William Lipa
Publikováno v:
Biomedicines
Volume 9
Issue 10
Biomedicines, Vol 9, Iss 1348, p 1348 (2021)
Volume 9
Issue 10
Biomedicines, Vol 9, Iss 1348, p 1348 (2021)
Background: Alzheimer’s disease (AD) is the major cause of age-associated cognitive decline, and in the absence of effective therapeutics is progressive and ultimately fatal, creating a dire need for successful prevention and treatment strategies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d85d67afc14fd444e45d051daa1a511b
https://pubmed.ncbi.nlm.nih.gov/34680464
https://pubmed.ncbi.nlm.nih.gov/34680464
Autor:
Veronica Galvan, Surita Banwait, Patricia Spilman, Olivia F. Gorostiza, Alyson Peel, Marina Ataie, Danielle Crippen, Wei Huang, Gurleen Sidhu, Hidenori Ichijo, Dale E. Bredesen
Publikováno v:
Neurobiology of Disease, Vol 28, Iss 1, Pp 65-75 (2007)
The amyloid precursor protein (APP) is a type I transmembrane protein translocated to neuronal terminals, whose function is still unknown. The C-terminus of APP mediates its interaction with cellular adaptor and signaling proteins, some of which sign
Externí odkaz:
https://doaj.org/article/8fbd6bc8bf974d6484890cb67c2ac3ee
Autor:
Alyson L Peel, Dale E Bredesen
Publikováno v:
Neurobiology of Disease, Vol 14, Iss 1, Pp 52-62 (2003)
Accumulation of amyloid β peptides (Aβ) in the brain, which is a hallmark of Alzheimer’s disease (AD), is associated with progressive damage to neuronal processes resulting in extensive neuritic dystrophy. This process may contribute to cognitive
Externí odkaz:
https://doaj.org/article/b9779c7fd72949caaddf38e8577c2a39